A New Award from MSCRF to Lentigen Technology, Inc. to Commercialize Curative Approaches for Sickle Cell Disease
Developing a new gene vector, and a point-of-care manufacturing platform, hematopoietic stem cells will be engineered as a means to treat sickle cell disease GATIHERSBURG, MARYLAND, MD, UNITED STATES, June 5, 2026 /EINPresswire.com/ -- Lentigen …